Crossmark

Temple syndrome in a patient with variably methylated CpGs at the primary MEG3/DLK1:IG-DMR and severely hypomethylated CpGs at the secondary MEG3:TSS-DMR

Crossref DOI link: https://doi.org/10.1186/s13148-019-0640-2

Published Online: 2019-03-07

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kagami, Masayo http://orcid.org/0000-0003-3020-455X
Yanagisawa, Atsuhiro

Ota, Miyuki

Matsuoka, Kentaro

Nakamura, Akie

Matsubara, Keiko

Nakabayashi, Kazuhiko

Takada, Shuji

Fukami, Maki

Ogata, Tsutomu
Funding

Funding for this research was provided by:

Japan Agency for Medical Research and Development (JP17ek0109141, JP18ek0109373)

National Center for Child Health and Development (28-3)

Japan Society for the Promotion of Science (15K15096)

Takeda Science Foundation (No number)
License Information

Text and Data Mining valid from 2019-03-07

Version of Record valid from 2019-03-07
More Information

Article History

Received: 27 December 2018

Accepted: 28 February 2019

First Online: 7 March 2019

Ethics approval and consent to participate

: Approval to conduct this study was obtained from the Ethical Committee of the Institutional Review Board Committee at the National Center for Child Health and Development (518).

: We obtained written informed consent from the patient or the patient’s parents to publish patient’s clinical and molecular information as well as facial photographs.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below